Loss and reduction of Fez1 were correlated with a higher prevalence of lymph node metastases (71% vs. 0%, p = 0.061), although the same was not true for distant metastases or tumor stage. This evidence concerns the gene FEZ1 and metastatic malignant neoplasm in the lymph nodes.